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Recent studies have assessed the role of low molecular weight pro-
tein tyrosine phosphatase (LMW-PTP) in cell transformation and
tumour onset and progression, observing a significant increase in
the expression of LMW-PTP mRNA and protein in human breast,
colon, bladder and kidney tumour samples. Moreover, its enhanced
expression is generally prognostic of a more aggressive cancer. To
better understand the role of this protein during colon carcinogene-
sis and to study whether its overexpression is also observed in ear-
lier phases of carcinogenesis, we studied its expression in colon
tumours, induced in rats by treatment with 1,2-dimethylhydrazine
(DMH), an animal model that resemble the sequential formation of
histopathological lesions of spontaneous carcinogenesis in humans.
The results show a significant increase in LMW-PTP expression in
adenocarcinomas, suggesting that this phenomenon is associated
with the onset of malignancy. Moreover a significant overexpres-
sion of LMW-PTP transcript is associated with tumours originat-
ing in the proximal (right) part of the colon, confirming an observa-
tion already reported for human colon cancer.
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Protein tyrosine phosphorylation plays a key role in the genera-
tion of signals necessary for different cellular events such as
growth, migration and invasion of normal and malignant cells.1
Tumour onset and progression is clearly correlated with the action
of different tyrosine kinases,1,2 which are also considered reliable
markers of cancer progression.3,4 Recent evidence indicates that
phosphotyrosine protein phosphatases (PTPs) are also very impor-
tant in modulating the cell phosphorylation. Almost 70 different
enzymes are recognised to be part of the PTP superfamily,5 among
which low molecular weight protein tyrosine phosphatase (LMW-
PTP) is a 18-kDa enzyme that is widely expressed in different tis-
sues (for a review see Raugei et al.).6 LMW-PTP have been shown
to interact with several receptor tyrosine kinases and docking pro-
teins, including platelet-derived growth factor receptor (PDGF-
R),7 ephrin A2 receptor (EphA2)8,9 and b-catenin.10 The role of
LMW-PTP in cell transformation has been investigated by Kikawa
et al.,8 who demonstrated that LMW-PTP is frequently overex-
pressed in many oncogene-transformed or human tumour-derived
epithelial cells and that the overexpression of LMW-PTP is suffi-
cient to confer transformation to non-transformed epithelial cells.8
Chiarugi et al.11 demonstrated that LMW-PTPs act as positive
regulators of tumour onset and progression, showing that LMW-
PTP-transfected NIH3T3 fibroblasts engrafted in nude mice
induce the onset of larger fibrosarcomas, probably due to the
LMW-PTP dependent ephrin A2 receptor (EphA2) tyrosine
dephosphorylation.11 This condition is highly associated with
many human cancers and has also been observed also in prostate-
derived tumour cell lines.9 Recently, a significant increase in the
expression of LMW-PTP mRNA and protein level was observed
in malignant samples of breast, colon, bladder and kidney.12 It
was also found that colon cancers with increased LMW-PTP
mRNA expression were correlated with unfavorable outcome, thus
suggesting that LMW-PTP may be considered an oncogene.
To better understand the role of this protein during colon carci-
nogenesis and to determine whether over-expression of this gene
is also observed in earlier phases of carcinogenesis, such as in
adenomas (i.e. benign tumours), we studied LMW-PTP expression
in a well defined experimental model such as colon tumourigene-
sis induced in rats by administration of 1,2-dimethylhydrazine
(DMH), a specific colon carcinogen. In this model, colon cancer
develops through the sequential formation of histopathological
lesions similar to those observed in spontaneous carcinogenesis in
humans,13 thus allowing the study of the various stages of cancer
formation (preneoplastic lesions, adenomas, carcinomas).
Material and methods
Tumour induction
Male F344 rats were obtained from Nossan, Correzzana, Milan,
Italy, housed in plastic cages with wire tops, maintained at a tem-
perature of 22C, with a 12-hr light-dark cycle. Animal care fol-
lowed the European Union Regulations on the Care and Use of
Laboratory Animals. The experimental protocol was approved by
a local Ethical Committee for Animal Experimentation, Florence,
Italy and by the Commission for Animal Experimentation of the
Ministry of Health, Rome, Italy. To induced carcinogenesis, rats
received 10 injections (s.c.) of DMH (30 mg/kg body weight; dis-
solved in sterile saline and buffered with sodium hydroxide at neu-
tral pH) at 1 week intervals (total dose 300 mg/kg body weight).
Animals were sacrificed 16 weeks after the last injection with the
carcinogen.
Evaluation of the tumours
At sacrifice, the colon was macroscopically examined for the
presence and location of tumours or other pathological lesions.
Tissues showing a deviation from normal morphology were fixed
in 10% buffered formalin and embedded in paraffin blocks. Sam-
ples of tumour tissue and of apparently normal mucosa were also
harvested and stored at 280C until analysis for RT-PCR (see
below). Paraffin blocks were sectioned and stained with hematox-
ylin-eosin to confirm the presence and type of tumours by histo-
pathological examination, which was performed by a pathologist
unaware of the codes of the specimens. Before being fixed in for-
malin, suspected macroscopic lesions were measured with a cali-
per and their dimensions were calculated by multiplying the two
main diameters of each lesion. Cancer histological types were
evaluated on the basis of the histotype, grading and pattern of
growth; adenomas were classified according to Morson et al.14
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RNA extraction
Tissues were disrupted by homogenization in guanidine isothio-
cyanate-containing lysis Qiagen buffer (Qiagen, Valencia, CA).
Total RNA was extracted with QIAshredder and RNeasy MiniKit
Qiagen1 columns. RNA was eluted with 50 ll of ribonuclease
free water. Samples were treated with ribonuclease free DNase
Set1 (Qiagen, Valencia, CA) to eliminate DNA. Total RNA con-
centrations were determined with the GeneQuant spectrophotome-
ter (Amersham Biosciences, GE Healthcare, NJ).
Quantitative mRNA evaluation
The primers-probe set for mRNA quantification with the ABI
Prism 7700 Sequence Detection System was selected by the pro-
prietary software Primer Express. To evaluate the total amount of
LMW-PTP mRNA, we chose the forward primer at 10 nucleotides
from the ATG and the reverse primer starting from nucleotide 82
into the rat coding sequence, while the internal MGB1 (TaqMan1
Minor Groove Binder; PE Applied Biosystems) probe labelled
with FAMTM hybridised on 35–61 nts of coding sequence (Table I).
The mRNA of 483 bp (158 amino acids) did not present any
intron, and for that reason the FAM probe did not hybridise on the
intron–exon junction, as usual. The gene data are available at
NCBI Blast Rat sequence website (www.ncbi.nlm.nih.gov/
genome/seq/BlastGen/ accession number gi:62650885). The gene
is located on chromosome 6 (6q24).
To generate the reference curve, we used cDNA derived from
plasmids containing rat LMW-PTP cDNA. One microgram of the
plasmid was linearised and transcribed to RNA using Ribo-Max1
(Promega, Madison, WI). A standard curve was obtained by serial
dilution, from 3 3 107 to 3 3 102 copies. To evaluate LMW-PTP
mRNA expression in unknown samples, 400 ng of total RNA
were reverse-transcribed in 80 ll of final volume in a reaction
mixture containing 10 ll TaqMan1 RT buffer, 5.5 mM MgCl2,
500 lM each dNTPs, 2.5 lM random hexamers, 0.4 U/ll RNase
inhibitors and 1.25 U/ll MultiScribe reverse transcriptase
(Applied Biosystems, CA). The real time PCR reaction was
performed with 25 ng/5 ll cDNA, in a reaction mix containing
300 nM of each primer, 12.5 ll Universal Master Mix and 200 nM
of fluorescent probe. Plates were treated for 20 at 50C, 100 at
95C and then submitted to 40 cycles of amplification at 95C for
15 sec, 60C for 60 sec in the ABI Prism 7700 Sequence Detector
(Applied Biosystems, CA). All samples were run in duplicate.
Results were expressed as mRNA copies/lg total RNA. GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) mRNA expression
was also tested in each sample to verify the RNA integrity.
TABLE I – PRIMERS FOR AMPLIFICATION OF RAT LMW-PTP
Amplicons Primers
Total Forward: 50-GGG TCC AAG TCA GTG CTG
TTC-30
LMW-PTP Reverse: 50-CGT TTT CAT CAG TTA CCA
ATT TTC TG-30
probe(MGB1, FAMTM): 50-TGT GTC TCG
GTA ACA TTT GCC GGT CA-30
FIGURE 1 – LMW-PTP expression in cancer tissues and in paired
normal mucosa. Total LMW-PTP mRNA was subjected to real-time
PCR quantitative analysis. n 5 22. ¤ : significantly different when
compared with normal paired mucosa, p5 0.0016.
FIGURE 2 – The 22 total samples were sorted according to their his-
topathology, generating a group of 7 adenomas and 15 carcinomas.
LWM-PTP expression was determined as in Figure 1. ¤ : significantly
different when compared with normal paired mucosa, p5 0.0047.
FIGURE 3 – Samples were sorted according to their localization,
left-distal (n 5 12) or proximal-right (n 5 10). LWM-PTP expression
was determined as in Figure 1. ¤ : significantly different when com-
pared with normal paired mucosa, p5 0.001.
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Statistical evaluation
Data obtained from the different samples were summarized for
quantitative continuous responses by calculating group means and
standard deviations and errors. Differences in expression between
tumours and their paired normal mucosa were evaluated with Stu-
dent’s t test for paired samples. Values of p < 0.05 were consid-
ered significant.
Results
Colon tumours (n 5 22) were induced in rats by treatment with
DMH. The histopathological analysis of these tumours showed
that 7 of them were adenomas and fifteen adenocarcinomas. The 7
adenomas were all of tubular type, six of them showed severe dys-
plasia, while the dysplasia in one was moderate. Twelve of the
adenocarcinomas still retained a high grade of differentiation,
while the differentiation was moderate in three. The level of inva-
sion in 10 tumours was confined to the mucosa, in 3 to the sub-
mucosa, while in 2 tumours it was not possible to evaluate this
parameter. The expression of LMW-PTP was analyzed in 22 sam-
ples of colonic tumours together with their apparently paired
normal mucosa. The results revealed a significant (p 5 0.0016)
overall increase in LMW-PTP expression of about 2.5-fold in
tumour samples as compared with their paired normal mucosa
(Fig. 1).
To evaluate whether there was a difference in the expression of
LMW-PTP according to the tumour histological type, the samples
were divided into adenomas and adenocarcinomas, generating 2
groups of 7 adenomas and 15 adenocarcinomas. This analysis
shows that the nearly 3-fold LMW-PTP increase is highly signifi-
cant in adenocarcinoma samples (p 5 0.0047), while the 2-fold
increase observed in the adenoma samples did not attain statistical
significance (p 5 0.1834) (Fig. 2).
Since we already had some hints that LMW-PTP over-expres-
sion may be different in distinct locations of the colon,12 the colo-
nic tumours were also sorted according to location, with 12
tumour samples originating in the left distal side and 10 from the
right proximal site. The 22 tumours analyzed were evenly distrib-
uted on the right and left side of the colon, with 3 adenomas and 8
carcinomas on the left side and 3 adenomas and 7 carcinomas on
the right side. The results (Fig. 3) show that while the 3-fold dif-
ference in LMW-PTP expression between tumour samples and
paired adjacent tissue was highly significant for right side lesions
(p 5 0.001), this was not the case for left side tumours, although a
2-fold increase can be observed also in these tumour samples.
Interestingly, when sorting the tumours according to their location
(left or right) and their type (adenomas and carcinomas) we
observed (Fig. 4) that while carcinomas in both locations show
increased LMW-PTP expression (and, notably, attaining statistical
significance at the right site, with p 5 0.007), only the adenomas
located on the right side were different from normal mucosa,
although with no statistical significance.
Discussion
The malignant transformation of colorectal epithelium into can-
cer is a multistage process, leading to adenoma and sequentially to
carcinoma formation. The evolution of colorectal cancer is
thought to proceed on the basis of accumulation of genetic altera-
tions including not only mutations in various genes such as APC
or K-ras but also epigenetic events.15,16
In a previous work we observed that LMW-PTP overexpression
in human colon cancer was significantly correlated with unfavora-
ble predictive markers such as lymphnode involvement, advanced
Duke’s stage, lower differentiation and un unfavorable outcome.12
In the present work we observe a significant increase in the
expression of LMW-PTP in colonic tumours induced in rats by
DMH. Since within this experimental model, tumourigenesis
evolves through a sequence similar to that observed in humans,
i.e. through the sequential formation of adenomas and carcinomas,
it was also possible to study LMW-PTP in the various phases of
the process. The results indicate that there was a significant
increase in LMW-PTP expression in adenocarcinomas, but that
the 2-fold increase in the expression observed also in adenomas,
did not attain statistical significance. These results suggest that the
overexpression of LMW-PTP is a phenomenon associated with
the onset of malignancy. Notably, when we classified the tumours
according to their location, i.e. whether they were formed in the
distal (left colon) or in the proximal (right) part of the colon, we
found that there was a significant increase in the expression of
LMW-PTP only in the proximal tumours when compared with the
normal mucosa, while this effect was not significant in the distal
tumours. Moreover, the results obtained sorting the tumours
according to their location and their type, show that the most sig-
nificant effect in term of increase of LMW-PTP expression is
FIGURE 4 – LMW-PTP expression in
cancer tissue and paired normal mucosa
was sorted according to localization and
histopathology. LMW-PTP expression was
determined as in Figure 1. ¤ : significantly
different when compared with normal
paired mucosa, p5 0.007.
1677EXPRESSION OF LMW-PTP
observed in the carcinomas located at the right site. It is interesting
to note that in the previous report on human colon cancers we
observed a significant increase in LMW-PTP in both left and right
tumours, but the expression in the right tumours was higher than
that observed in those originating in the left colon.12 These previ-
ous results together with the present ones are thus in line with sev-
eral reports suggesting that right and left colon cancers are differ-
ent entities with distinct molecular and cellular characteristics, a
different etiology and sensitivity to chemotherapy.17–20
The present study may contribute to a better molecular-based
classification of CRC, LMW-PTP overexpression being an addi-
tional marker of malignancy, according to our previous results in
human colon cancer. These results also suggest that CRC tumours
of right and left origin might be 2 partially distinct forms of cancer.
Our previous results indicate ephrin A2 receptor (EphA2) as a
LMW-PTP target that may be responsible for oncogenic action
due to the overexpression of tyrosine phosphatase.9,11 In fact,
EphA2 tyrosine dephosphorylation has been associated with
several different human cancers.21
On these basis it is possible to speculate that LMW-PTP over-
expression in adenocarcinomas and consequent EphA2 tyrosine
dephosphorylation may be one of the effect responsible for adeno-
carcinoma development. Nevertheless, it cannot be excluded that
other unknown substrates may exert important tumourigenic
actions following their LMW-PTP-dependent tyrosine dephospho-
rylation. For this reason further analysis of the targets of LMW-
PTP action may further contribute to understanding of its role in
the development of colon cancer.
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